What Is BPC-157? A Complete Peptide Guide

BPC-157, short for Body Protection Compound-157, is a pentadecapeptide (15 amino acids) with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a larger protein called BPC (Body Protection Compound) that is naturally present in human gastric juice at nanogram concentrations.

First isolated and characterized in the early 1990s by Professor Predrag Sikiric and colleagues at the University of Zagreb, BPC-157 has been the subject of extensive preclinical research spanning over three decades. Unlike many synthetic peptides, BPC-157 is remarkably stable — it resists degradation in acidic environments and does not require carrier proteins for activity.

BPC-157 is classified as a research peptide and is not FDA-approved for any medical condition. However, it has accumulated one of the largest bodies of preclinical evidence of any peptide in the regenerative category, spanning muscle, tendon, ligament, bone, gut, brain, and vascular tissue repair.

BPC-157's therapeutic potential stems from its ability to influence multiple biological pathways simultaneously:

• Angiogenesis: BPC-157 upregulates VEGF (vascular endothelial growth factor), promoting new blood vessel formation and improving blood supply to damaged tissues.
• Nitric Oxide System: It modulates the NO system, influencing vasodilation, blood pressure regulation, and tissue protection. BPC-157 can counteract both NO-excess and NO-deficiency states.
• Growth Factor Modulation: The peptide upregulates EGF (epidermal growth factor), FGF (fibroblast growth factor), and other repair-related growth factors.
• FAK-Paxillin Pathway: BPC-157 activates the focal adhesion kinase pathway, critical for cell migration, adhesion, and wound healing.
• Dopamine System: Research shows BPC-157 interacts with the dopaminergic system, offering potential neuroprotective and mood-related benefits.
• Anti-Inflammatory: While not a traditional anti-inflammatory, BPC-157 modulates inflammatory cascades to support resolution rather than suppression of inflammation.

Based on the available preclinical research, BPC-157 has demonstrated potential benefits across numerous systems:

• Musculoskeletal Repair: Accelerated healing of tendons, ligaments, muscles, and bones in animal models. This is the most commonly cited use case.
• Gut Health: Protective effects against NSAID-induced gastric ulcers, inflammatory bowel disease models, and intestinal damage. As a gastric juice-derived peptide, gut healing is considered a primary function.
• Neuroprotection: Protection against traumatic brain injury, peripheral nerve damage, and dopaminergic neurotoxicity in rodent studies.
• Vascular Healing: Promotion of blood vessel repair and protection against endothelial dysfunction.
• Organ Protection: Demonstrated protective effects on the liver, pancreas, and heart in various damage models.
• Wound Healing: Enhanced skin wound closure, burn healing, and surgical wound recovery in animal models.

It is important to note that while the breadth of preclinical evidence is impressive, human clinical trial data remains limited.

Common BPC-157 administration protocols discussed in research and community contexts include:

• Subcutaneous Injection: 250–500 mcg once or twice daily. This is the most common route. Injections are typically administered near the site of injury for localized effects or in the abdominal area for systemic effects.
• Oral Administration: 500–1000 mcg daily. BPC-157 is unusually stable in the GI tract, and oral dosing has shown efficacy in gastric and intestinal healing studies.
• Cycle Duration: Typical protocols run 4–8 weeks. Some users cycle off for 2–4 weeks before repeating.
• Reconstitution: Lyophilized BPC-157 is reconstituted with bacteriostatic water. Standard vials contain 5 mg of peptide.

Disclaimer: These dosages are drawn from preclinical research and community discussion. Always work with a healthcare provider to determine appropriate dosing for your individual situation.

BPC-157 has demonstrated a remarkably favorable safety profile in preclinical studies:

• No reported lethal dose (LD50): Toxicology studies have not been able to establish a lethal dose, even at extremely high concentrations.
• Common minor effects: Mild injection site redness, slight nausea (particularly with oral dosing at higher doses), and temporary dizziness have been occasionally reported anecdotally.
• No significant organ toxicity: Available studies have not shown liver, kidney, or cardiac toxicity.
• Theoretical concerns: Because BPC-157 promotes angiogenesis, theoretical concerns exist about its use in individuals with active cancers (new blood vessel formation could potentially support tumor growth). This remains theoretical and unproven.

Despite the favorable safety data, the lack of large-scale human trials means the full side effect profile is not yet established. Caution is warranted, particularly for individuals with cancer, pregnant or nursing women, and those on blood-thinning medications.

The peptide market varies enormously in quality. Many vendors sell underdosed, impure, or misidentified products. When purchasing BPC-157, look for:

• Third-Party COAs: Certificate of Analysis showing HPLC purity (>98%) and mass spectrometry confirmation.
• Batch-Level Testing: Each production batch should be independently tested, not just a single representative sample.
• Proper Storage: BPC-157 should be shipped lyophilized (freeze-dried) and stored frozen or refrigerated.
• Transparent Practices: Legitimate vendors are transparent about their sourcing, manufacturing, and testing protocols.

We recommend Ascension Peptides as a top-tier source for BPC-157. They provide batch-specific COAs, maintain rigorous quality control, and have built a strong reputation in the peptide community for consistent purity and potency.